Tech Company Financing Transactions
OriCell Therapeutics Funding Round
On 8/1/2022, OriCell Therapeutics raised $120 million in Series B financing from Qiming Ventures, Quan Capital and C&D Emerging Investment.
Transaction Overview
Company Name
Announced On
8/1/2022
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds for the development of its cell therapy pipeline, and the proprietary discovery platform, as well as for the construction of a manufacturing plant for both clinical and commercial purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3F Bldg 1, No. 1227 Zhangheng Rd, Pudong,
Shanghai, 200120
CN
Shanghai, 200120
CN
Phone
Website
Email Address
Overview
Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. We have received a pre-A round exclusive investment of nearly 100 million yuan from Qiming Venture Partners at the end of 2019 and completed the A round of financing worth over 200 million Yuan at the end of 2020.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yang Huanfeng
Chief Scientific Officer
He Xiaowen
Chief Technical Officer
Weidong Cui
Browse more venture capital transactions:
Prev: 8/1/2022: Li Industries venture capital transaction
Next: 8/1/2022: Tartan venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs